Purpose Of Review: Although the production and use of engineered nanomaterials (ENMs) is rapidly increasing, we lack sufficient knowledge regarding their capacity to induce and/or promote allergic disease. As novel ENMs are being developed and used for biomedical applications, such as drug delivery, it will be critical to understand the relationship between physicochemical properties of ENMs and possible mechanisms of immunomodulation.
Recent Findings: Cellular studies and a few animal studies have begun to examine the immunomodulatory effects of ENM exposure that may be predictive of developing allergic reactions. Specifically, the effects of direct ENM exposure on key immune cells recognized to facilitate allergic disease has been evaluated and will be discussed. However, few studies have reported specific physicochemical properties of ENMs that initiate allergic immune responses. Although limited, these descriptive studies point to the induction of cellular mechanisms that are well known to promote allergic disease.
Summary: The limited data currently available suggest that there is a potential risk for the development of allergic responses following exposure to ENMs. As more ENMs are developed for consumer products and nanomedicines, further study on their potential for adverse immune interactions will be necessary for safe implementation of these novel materials.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083400 | PMC |
http://dx.doi.org/10.1097/ACI.0000000000000031 | DOI Listing |
Front Immunol
March 2025
Laboratory of Translational Medicine Research, Deyang People's Hospital of Chengdu University of Traditional Chinese Medicine, Deyang, China.
Tissue-resident memory T (T) cells are a specialized subset of memory T cells that permanently reside in non-lymphoid tissues, providing localized and long-lasting immune protection. In the urinary tract, T cells play critical roles in defending against infections, mediating tumor immunity, and influencing the pathogenesis of chronic inflammatory diseases. Their therapeutic potential is immense, with promising avenues for vaccine development, enhanced cancer immunotherapy, and targeted treatments for chronic inflammation.
View Article and Find Full Text PDFIndian J Otolaryngol Head Neck Surg
January 2025
Department of Endocrinology, Joshi Clinic, Mumbai, India.
Allergen immunotherapy (AIT), or specific immunotherapy (SIT), is an effective treatment for inducing immune tolerance to specific allergens. It is widely used for allergic rhinitis, conjunctivitis, asthma, and Hymenoptera venom allergies, with recent applications to food allergies and atopic dermatitis. Despite its benefits, the use of SIT in patients with autoimmune diseases is controversial due to concerns about its potential to induce or exacerbate autoimmune conditions.
View Article and Find Full Text PDFJ Asthma Allergy
March 2025
The Second Hospital of Shanxi Medical University, Taiyuan, People's Republic of China.
Background: The lifting of the regional blockade in early December 2022 in Shanxi Province, China, caused an epidemic of Coronavirus disease 2019 (COVID-19). And the high allergy season from July to September each year.
Purpose: To investigate the effect of the COVID-19 epidemic on the respiratory sensitivity status of the population, to provide a scientific and effective basis for the prevention, diagnosis, condition assessment, and treatment of allergic respiratory diseases.
J Inflamm Res
March 2025
Department of Otorhinolaryngology & Clinical Allergy Center, The First Affiliated Hospital, Nanjing Medical University, Nanjing, People's Republic of China.
Purpose: Allergic rhinitis (AR), a chronic inflammatory disease of nasal mucosa, is considered as a classic Th2-mediated disease. We aimed to elucidate the molecular mechanisms and therapeutic potential of microRNAs (miRNAs) in AR.
Methods: Nasal mucosa was collected from patients with mite-sensitized AR and non-allergic controls for miRNA and mRNA sequencing.
Int J Cancer
March 2025
Department of Pharmacy, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Eosinophil-induced adverse events (Eo-irAEs) have been observed in patients treated with programmed cell death 1/ligand 1 (PD-1/PD-L1) inhibitors. Surprisingly, the clinical features and outcomes of Eo-irAEs induced by PD-1/PD-L1 inhibitors have not yet been elucidated. This study investigated the characteristics of and risk factors for Eo-irAEs induced by PD-1/PD-L1 inhibitors.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!